Plan to “Institutionalize” Key Premium Ditched for FY2014 Revision; Status Quo to Remain
To read the full story
Related Article
- Premium for Innovativeness or Usefulness (I) Set as Prerequisite for 10% “Precursor Premium”
December 20, 2013
- Generic Share Fails to Meet FY2012 Target but Reaches 47% in New Calculation Method
December 20, 2013
- Chuikyo Subcommittee Agrees on 60% Rule for First Generic Prices, 70% for Biosimilars
December 19, 2013
- Off-Patent Drugs to Get Continuous Price Cuts Until 60% Generic Share Reached
December 19, 2013
REGULATORY
- Health Minister Acknowledges Changes after 2016 Decision on Off-Year Revisions
May 28, 2024
- MHLW Panel OKs Avigan for SFTS with Strings Attached, Shionogi COVID Jab Only for Primary Use
May 27, 2024
- LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
May 24, 2024
- MHLW Proposes Inclusion of Prevenar 20 in National Immunization for Children
May 24, 2024
- MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report
May 23, 2024
Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…